Radiotherapy Combined With Endostatin and Capecitabine for NPC

Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.

Trial Details

NCT ID
NCT05514275
Phase
PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Endostatin and Capecitabine
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Jiaxing, Zhejiang, China|30.7522,120.75
  • Jinhua, Zhejiang, China|29.10678,119.64421
  • Lishui, Zhejiang, China|28.46042,119.91029
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO) histologically type).
  • Tumor staged as T3-4N1/N2-3 (according to the 8th American Joint Commission on Cancer edition).
  • No evidence of distant metastasis (M0). Satisfactory performance status: Karnofsky scale (KPS) \> 70. Adequate marrow: leucocyte count ≥4000/μL, he…
  • Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) \<1.5×upper limit of normal (ULN) concomitant with alka…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →